APLS Quote, Financials, Valuation and Earnings

Biomarin Pharmaceutical has a net margin of -29.19% compared to Apellis Pharmaceuticals's net margin of 14.23%. Apellis Pharmaceuticals's return on equity of -104.65% beat Biomarin Pharmaceutical's return on equity of 6.29%.

Apellis Pharmaceuticals has a consensus price target of $45.75, signalling upside risk potential of 37.31%. On the other hand Biomarin Pharmaceutical has an analysts' consensus of $98.08 which suggests that it could grow by 47.2%. Given that Biomarin Pharmaceutical has higher upside potential than Apellis Pharmaceuticals, analysts believe Biomarin Pharmaceutical is more attractive than Apellis Pharmaceuticals.

Apellis Pharmaceuticals has a beta of 0.939, which suggesting that the stock is 6.145% less volatile than S&P 500. In comparison Biomarin Pharmaceutical has a beta of 0.295, suggesting its less volatile than the S&P 500 by 70.544%.

Apellis Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biomarin Pharmaceutical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Apellis Pharmaceuticals pays -- of its earnings as a dividend. Biomarin Pharmaceutical pays out -- of its earnings as a dividend.

Apellis Pharmaceuticals quarterly revenues are $196.8M, which are smaller than Biomarin Pharmaceutical quarterly revenues of $745.7M. Apellis Pharmaceuticals's net income of -$57.4M is lower than Biomarin Pharmaceutical's net income of $106.1M. Notably, Apellis Pharmaceuticals's price-to-earnings ratio is -- while Biomarin Pharmaceutical's PE ratio is 39.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Apellis Pharmaceuticals is 5.73x versus 4.75x for Biomarin Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.

Ionis Pharmaceuticals has a net margin of -29.19% compared to Apellis Pharmaceuticals's net margin of -104.98%. Apellis Pharmaceuticals's return on equity of -104.65% beat Ionis Pharmaceuticals's return on equity of -93.21%.

Apellis Pharmaceuticals has a consensus price target of $45.75, signalling upside risk potential of 37.31%. On the other hand Ionis Pharmaceuticals has an analysts' consensus of $61.36 which suggests that it could grow by 67.97%. Given that Ionis Pharmaceuticals has higher upside potential than Apellis Pharmaceuticals, analysts believe Ionis Pharmaceuticals is more attractive than Apellis Pharmaceuticals.

Apellis Pharmaceuticals has a beta of 0.939, which suggesting that the stock is 6.145% less volatile than S&P 500. In comparison Ionis Pharmaceuticals has a beta of 0.349, suggesting its less volatile than the S&P 500 by 65.148%.

Apellis Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ionis Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Apellis Pharmaceuticals pays -- of its earnings as a dividend. Ionis Pharmaceuticals pays out -- of its earnings as a dividend.

Apellis Pharmaceuticals quarterly revenues are $196.8M, which are larger than Ionis Pharmaceuticals quarterly revenues of $133.8M. Apellis Pharmaceuticals's net income of -$57.4M is higher than Ionis Pharmaceuticals's net income of -$140.5M. Notably, Apellis Pharmaceuticals's price-to-earnings ratio is -- while Ionis Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Apellis Pharmaceuticals is 5.73x versus 6.64x for Ionis Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of -29.19% compared to Apellis Pharmaceuticals's net margin of 0.7%. Apellis Pharmaceuticals's return on equity of -104.65% beat Moderna's return on equity of -17.44%.

Apellis Pharmaceuticals has a consensus price target of $45.75, signalling upside risk potential of 37.31%. On the other hand Moderna has an analysts' consensus of $127.09 which suggests that it could grow by 84.23%. Given that Moderna has higher upside potential than Apellis Pharmaceuticals, analysts believe Moderna is more attractive than Apellis Pharmaceuticals.

Apellis Pharmaceuticals has a beta of 0.939, which suggesting that the stock is 6.145% less volatile than S&P 500. In comparison Moderna has a beta of 1.582, suggesting its more volatile than the S&P 500 by 58.238%.

Apellis Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Apellis Pharmaceuticals pays -- of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

Apellis Pharmaceuticals quarterly revenues are $196.8M, which are smaller than Moderna quarterly revenues of $1.9B. Apellis Pharmaceuticals's net income of -$57.4M is lower than Moderna's net income of $13M. Notably, Apellis Pharmaceuticals's price-to-earnings ratio is -- while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Apellis Pharmaceuticals is 5.73x versus 3.08x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

QuidelOrtho has a net margin of -29.19% compared to Apellis Pharmaceuticals's net margin of -2.74%. Apellis Pharmaceuticals's return on equity of -104.65% beat QuidelOrtho's return on equity of -47.52%.

Apellis Pharmaceuticals has a consensus price target of $45.75, signalling upside risk potential of 37.31%. On the other hand QuidelOrtho has an analysts' consensus of -- which suggests that it could grow by 14.72%. Given that Apellis Pharmaceuticals has higher upside potential than QuidelOrtho, analysts believe Apellis Pharmaceuticals is more attractive than QuidelOrtho.

Apellis Pharmaceuticals has a beta of 0.939, which suggesting that the stock is 6.145% less volatile than S&P 500. In comparison QuidelOrtho has a beta of 0.107, suggesting its less volatile than the S&P 500 by 89.318%.

Apellis Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. QuidelOrtho offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Apellis Pharmaceuticals pays -- of its earnings as a dividend. QuidelOrtho pays out -- of its earnings as a dividend.

Apellis Pharmaceuticals quarterly revenues are $196.8M, which are smaller than QuidelOrtho quarterly revenues of $727.1M. Apellis Pharmaceuticals's net income of -$57.4M is lower than QuidelOrtho's net income of -$19.9M. Notably, Apellis Pharmaceuticals's price-to-earnings ratio is -- while QuidelOrtho's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Apellis Pharmaceuticals is 5.73x versus 1.06x for QuidelOrtho. Usually stocks with elevated PS ratios are considered overvalued.